Becton

BD Advances "One-Stick Hospital Stay" Vision with Launch of Next-Generation Needle-Free Blood Draw Technology

Retrieved on: 
Thursday, November 2, 2023
FDA, Becton, Standard of care, NYSE, Food, IV, Needlestick injury, Fear, Regulation of tobacco by the U.S. Food and Drug Administration, Health, Maintenance, BD, Clinical, BDX, Risk, Hospital, Workflow, Anxiety, Becton, Dickinson and Company headquarters, Patient, Medical imaging, Medical device

FRANKLIN LAKES, N.J., Nov. 2, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay."  

Key Points: 
  • New Peripheral Line Draw Solution Delivers First and Only Compatibility with Integrated Catheters, Bringing Elevated Standard of Care to More U.S.
  • Hospitals
    FRANKLIN LAKES, N.J., Nov. 2, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay."
  • **Clinical studies were done on previous generations of the PIVO™ Blood Collection Device and Nexiva™ Catheter System.
  • PIVO™ Pro and Nexiva™ with NearPort IV Access are the next generations of their respective product families.

BD Named Among the 100 Best Corporate Citizens of 2023

Retrieved on: 
Wednesday, October 18, 2023
Becton, NYSE, ESG, Sustainable Development Goals, History, Paris, Workforce, Responsibility, BD, Environment, BDX, Human rights, Health equity, Paris Agreement, Becton, Dickinson and Company headquarters, Climate change, Management

FRANKLIN LAKES, N.J., Oct. 18, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named to the 100 Best Corporate Citizens List by 3BL, which recognizes outstanding environmental, social and governance (ESG) transparency and performance among 1,000 of the largest U.S. public companies. This year, BD ranked second in the health care equipment and services industry.

Key Points: 
  • FRANKLIN LAKES, N.J., Oct. 18, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named to the 100 Best Corporate Citizens List by 3BL, which recognizes outstanding environmental, social and governance (ESG) transparency and performance among 1,000 of the largest U.S. public companies.
  • This year, BD ranked second in the health care equipment and services industry.
  • The 100 Best Corporate Citizens ranking is based on 184 ESG factors in seven pillars – climate change, employee relations, environment, governance, human rights, stakeholders and society, and ESG performance.
  • The 100 Best Corporate Citizens of 2023 are answering the call by demonstrating the societal and bottom-line value of leadership and transparency around ESG topics.

United States Cardiovascular Needle Market Insights and Forecast Report, 2022-2023 & 2026 - AI is Making Inroads in Cardiovascular Medicine, Improving Prognosis and Treatment Outcomes - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Health, Cardiology, Diagnosis, Cardiovascular disease, Nursing care plan, Infection, COVID-19, Disease, Injury, Becton, Dickinson and Company headquarters, Bleeding, Brain, Prevalence, Blunt cardiac injury, Artificial intelligence, AI, Risk, Heart, Mortality, Becton, Splenic infarction, Medtronic, BD, Type, Gesellschaft mit beschränkter Haftung, CVD, Society, Blood, Johns Hopkins, Growth, Surgical suture, ICU, Disorder, Tissue, Hospital, FSSB, Skin, Stroke, Needle, Prognosis, Birth, Patient, Surgeon, Fatality, Beauty salon, Pharmaceutical industry, Medical device, Silk

The US cardiovascular needle market is foreseen to reach US$36.71 million in 2023, growing at a CAGR of 7.55% during the forecasted period.

Key Points: 
  • The US cardiovascular needle market is foreseen to reach US$36.71 million in 2023, growing at a CAGR of 7.55% during the forecasted period.
  • The treatment of these disorders often requires specialized surgeries, during which cardiovascular needles are used to suture the wounds.
  • Consequently, the increasing prevalence of cardiovascular diseases has driven the demand for cardiovascular devices for diagnosis and treatment, contributing to the growth of the cardiovascular needle market in recent years.
  • Artificial intelligence (AI) is making inroads in cardiovascular medicine, improving prognosis and treatment outcomes.

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Retrieved on: 
Tuesday, October 17, 2023
BDX, NYSE, Becton, Dickinson and Company headquarters, PepsiCo, General Electric Company, Treasury, Terex, Becton, BD, Growth, Management, Boston College, Science

FRANKLIN LAKES, N.J., Oct. 17, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately.

Key Points: 
  • FRANKLIN LAKES, N.J., Oct. 17, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately.
  • Rodetis will continue to report to Chris DelOrefice, executive vice president and chief financial officer for BD.
  • Rodetis joined BD in 2016 as vice president and assistant treasurer, capital markets.
  • Prior to BD, Greg was with Terex Corporation as the assistant treasurer and prior to this he held roles of progressive responsibility with PepsiCo, Inc., and General Electric Company.

BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices

Retrieved on: 
Monday, October 16, 2023
Health, Hospital, BDX, Recycling, NYSE, Becton, Dickinson and Company headquarters, ESG, Casella Waste Systems, Municipal solid waste, State, Becton, BD, Syringe, Medical device, Biodegradable waste, Needle, Plastic, Casella

FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 (GLOBE NEWSWIRE) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Casella Waste Systems, Inc. (Nasdaq: CWST) (Casella), a solid waste, recycling, and resource management services company, today announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.

Key Points: 
  • The medical waste was collected across a variety of health care facilities and all of the plastics were diverted from disposal and recycled.
  • The pilot also assessed technical feasibility of two types of technology – mechanical and advanced recycling – both showing favorable results in their ability to successfully recycle used medical devices for use in other products.
  • The teams will also increase focus to cover other types of medical materials for recycling, as well as reclaiming the used devices and returning them to the manufacturing process.
  • “This pilot showcases the strength of collaborative partnerships when it comes to sustainable material management practices,” said Casella Chairman and CEO, John W. Casella.

BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices

Retrieved on: 
Monday, October 16, 2023
Needle, Health, Hospital, BDX, Recycling, NYSE, Becton, Dickinson and Company headquarters, ESG, Casella Waste Systems, Municipal solid waste, State, Becton, BD, Syringe, Medical device, Biodegradable waste, Plastic, Casella

FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Casella Waste Systems, Inc. (Nasdaq: CWST) (Casella), a solid waste, recycling, and resource management services company, today announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.  

Key Points: 
  • These containers included a broad range of medical equipment and materials, primarily syringes and needles.
  • The pilot also assessed technical feasibility of two types of technology – mechanical and advanced recycling – both showing favorable results in their ability to successfully recycle used medical devices for use in other products.
  • The teams will also increase focus to cover other types of medical materials for recycling, as well as reclaiming the used devices and returning them to the manufacturing process.
  • "This pilot showcases the strength of collaborative partnerships when it comes to sustainable material management practices," said Casella Chairman and CEO, John W. Casella.

BD to Announce Fiscal 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Thursday, October 12, 2023
News, NYSE, Becton, Dickinson and Company headquarters, Becton, BD, Rare-earth element, Financial adviser

FRANKLIN LAKES, N.J., Oct. 12, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will report its fiscal 2023 fourth quarter and full year financial results on Thursday, November 9, 2023.

Key Points: 
  • FRANKLIN LAKES, N.J., Oct. 12, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will report its fiscal 2023 fourth quarter and full year financial results on Thursday, November 9, 2023.
  • A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors , along with related presentation materials.
  • The news release and presentation materials will include summary financial information for the company's fiscal 2023 fourth quarter and full year financial results, which ended on Saturday, September 30, 2023.
  • ET on November 9, 2023 to discuss its financial results and provide an update on its operations and strategy.

Azenta Announces CFO Transition

Retrieved on: 
Tuesday, September 26, 2023
Bachelor of Science in Information Technology, Operation, Small business, Bard (company), Senior, Certified Public Accountant, Fairleigh Dickinson University, Becton, Dickinson and Company headquarters, Business administration, Secretary of State of New Jersey, Retirement, Acquisition, Becton, Master of Business Administration, Seton Hall University, BDX, NYSE, Management, Science, Finance, Azenta

BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD (Becton, Dickinson and Company, NYSE: BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition.

Key Points: 
  • BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16.
  • Mr. Cueto, who comes from BD (Becton, Dickinson and Company, NYSE: BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition.
  • Steve Schwartz, Azenta President and Chief Executive Officer, said, "We are thrilled to welcome Herman to Azenta.
  • Azenta is reaffirming its fourth quarter fiscal 2023 guidance provided in its third quarter 2023 earnings materials on August 8, 2023.

BD Ranks in Top 10 for Transparency, Awarded Best Code of Conduct in 2023 U.S. Transparency Awards

Retrieved on: 
Tuesday, September 19, 2023
Conduct, Becton, Dickinson and Company headquarters, Patient, ESG, Becton, BDX, NYSE, Behavior, BD, Pharmaceutical industry

"Particularly now, when stakeholders are evaluating the moral and ethical behaviors of companies, the code of conduct is the roadmap that provides insight into a company's values -- it guides and influences the behavior of its Board and employees," said Broc Romanek, industry-renowned expert and chair of the independent Transparency Scientific Committee, which will oversee the awards starting next year. "Among the many ways BD stood out among its peers, it provides a user-friendly interface, offers direct links to policies to ensure accessibility and includes an easy-to-understand graphic about the reporting process so that there can be no confusion."

Key Points: 
  • Each year, experts from Labrador evaluate the proxy statements, Form 10-Ks, investor relations websites, codes of conduct, and for the first time, ESG reports from the S&P 250.
  • The team collected more than 59,250 data points and reviewed each organization's disclosure documents using 237 objective criteria that reflect the award's five pillars of transparency: clarity, accessibility, precision, comparability and availability.
  • The Labrador experts reviewed 29 criteria specific to the code of conduct to determine the 2023 rankings.
  • For more information on the U.S. Transparency Awards, visit TransparencyAwards.com or RealTransparentDisclosure.com; and to learn more about BD, visit BD.com .

Navigate BioPharma Services, Inc. Announces Collaboration with BD (Becton, Dickinson and Company) to Advance Capabilities for Clinical Phases of Drug Development

Retrieved on: 
Thursday, September 7, 2023
Business development, Workflow, Biotechnology, Clinical trial, Cancer, Multimedia, Biomarker, Biopharma LLC, MRD, Becton, Dickinson and Company headquarters, Novartis, Patient, Automation, Drug combination, Flow cytometry, IVD, Becton, Navigation, Safety, BDX, NYSE, BD, Software, Medical device, Medical imaging, Mobile phone

Importantly, this collaboration aims to address a critical gap in the clinical trial field for an integrated solution provider from method development to commercialization.

Key Points: 
  • Importantly, this collaboration aims to address a critical gap in the clinical trial field for an integrated solution provider from method development to commercialization.
  • Vipin Bhambhani, VP of Clinical Flow Solutions, BD Biosciences said, "Flow cytometry is a powerful technique that can enable high-sensitivity, affordable testing with fast turnaround time.
  • Providing flexible and integrated solutions that can help collaborators achieve their clinical and regulatory goals by leveraging the capabilities of flow cytometry.
  • Over the past decade, Navigate BioPharma has built and developed its exclusive library of assays, methodologies, and biomarker solutions.